Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection

Pediatric Infectious Disease Journal

Volumn 20, Issue 7, 2001, Pages 666-671

  Kline, Mark W ^a   Brundage, Richard C ^b   Fletcher, Courtney V ^b   Schwarzwald, Heidi ^a   Calles, Nancy R ^a   Buss, Neil E ^c   Snell, Paul ^d   Delora, Patricia ^e   Eason, Monica ^e   Jorga, Karin ^c   Craig, Charles ^d   Duff, Frank ^e  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

Human immunodeficiency virus infection; Nelfinavir; Saquinavir soft gelatin capsules

Indexed keywords

ANTIRETROVIRUS AGENT; GELATIN; NELFINAVIR; SAQUINAVIR; VIRUS RNA;

ABDOMINAL DISCOMFORT; ADOLESCENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; STEADY STATE; VIRUS RESISTANCE;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAPSULES; CHILD; CHILD, PRESCHOOL; FEMALE; GELATIN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; NELFINAVIR; PROGNOSIS; REVERSE TRANSCRIPTASE INHIBITORS; SAQUINAVIR;

EID: 0034940996     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200107000-00006     Document Type: Article

References (24)

1. Randomized study of the tolerance and efficacy of high- vs. low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128)
2. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children
3. A randomized comparative trial of stavudine (d4T) vs. zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection
4. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus
5. A Phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
6. Clinical and immunovirologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection
7. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in the Netherlands
8. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir
9. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients
10. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues: Study of protease inhibitor combinations in Europe
11. 1994 revised classification system for human immunodeficiency virus infection in children <13 years of age
12. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus
13. Pharmacologic characteristics of indinavir, didanosine and stavudine in HIV-infected children receiving combination therapy
14. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
15. Saquinavir soft-gelatin capsule formulation, a review of its use in patients with HIV infection
16. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection
17. Effect of human immunodeficiency virus infection on the growth of young children
18. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children
19. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus infected infants and children
20. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
21. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children